Kissei Pharmaceutical
€0.000000
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
3AugExpected
Q1 2026
Next
0.34
0.38
0.41
0.44
Expected EPS
0.34470922061034315
Actual EPS
N/A
Financials
13.53%Profit Margin
Profitable548.36MRevenue
74.21MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow KIS.STU. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan. The company offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Minirin Melt OD tablets; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia. Its products in pipeline include CG0070, which is in Phase III clinical trial to treat non-muscle-invasive bladder cancer; Linzagolix, which is in Phase III clinical trial for the treatment of uterine fibroids and endometriosis; KDT-3594, which is in Phase II clinical trial to treat Parkinson's disease; KSP-0243 that is in Phase II clinical trial to treat Ulcerative colitis; and Difelikefalin, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. The company is also developing Silodosin for dysuria associated with benign prostatic hyperplasia; and Fostamatinib for tyrosine kinase inhibitor. In addition, it develops and sells protein controlled and energy supply food; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, facility and equipment management, and information gathering and development support services. Further, the company engages in the information equipment rentals; insurance agency business; manufactures and sells noodles; and undertakes construction of factories, research institutes, offices, etc., as well as computer system design and development, and cloud services. Kissei Pharmaceutical Co., Ltd. was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was incorporated in 1946 and is based in Matsumoto, Japan.
Show more...
CEO
Mr. Mutsuo Kanzawa
Employees
1786
Country
Japan
ISIN
JP3240600001
Listings
0 Comments
Share your thoughts
FAQ
What is Kissei Pharmaceutical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Kissei Pharmaceutical stocks are traded under the ticker KIS.STU.
When is the next Kissei Pharmaceutical earnings date?▼
Kissei Pharmaceutical is going to release the next earnings report on August 03, 2026.
What were Kissei Pharmaceutical earnings last quarter?▼
KIS.STU earnings for the last quarter are 0.36 EUR per share, whereas the estimation was 0.44 EUR resulting in a -18.5% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Kissei Pharmaceutical revenue for the last year?▼
Kissei Pharmaceutical revenue for the last year amounts to 548.36M EUR.
What is Kissei Pharmaceutical net income for the last year?▼
KIS.STU net income for the last year is 74.21M EUR.
How many employees does Kissei Pharmaceutical have?▼
As of July 10, 2026, the company has 1,786 employees.
In which sector is Kissei Pharmaceutical located?▼
Kissei Pharmaceutical operates in the Health & Wellness sector.
When did Kissei Pharmaceutical complete a stock split?▼
Kissei Pharmaceutical has not had any recent stock splits.
Where is Kissei Pharmaceutical headquartered?▼
Kissei Pharmaceutical is headquartered in Matsumoto, Japan.